Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rocuronium bromide
Drug ID BADD_D01960
Description Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. [Sugammadex] is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
Indications and Usage For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Marketing Status approved
ATC Code M03AC09
DrugBank ID DB00728
KEGG ID D00765
MeSH ID D000077123
PubChem ID 441351
TTD Drug ID D0L5CZ
NDC Product Code 55486-1593; 51662-1355; 71872-7036; 43547-531; 71288-700; 71872-7262; 43066-007; 51662-1546; 63323-426; 70860-651; 71872-7202; 71872-7207; 0781-3220; 12860-0450; 60722-1005; 64220-179; 55150-225; 65145-130; 68083-365; 71288-718; 72611-756; 72611-757; 17404-1022; 63592-0178; 67457-228; 68083-364; 0409-9558; 10695-023; 58175-0395; 65089-0018; 71839-141; 72572-651; 25021-662; 43547-530; 51662-1354; 65219-065; 0409-7037; 55486-1606; 39822-4200; 43066-013; 71839-142; 81565-204; 51662-1545; 65145-131; 0409-3189; 72572-650; 60870-0450; 0143-9250; 0143-9251; 55150-226
UNII I65MW4OFHZ
Synonyms Rocuronium | 1-(17-(Acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium | Androstane-3,17-diol, 2-(4-morpholinyl)-16-(1-(2-propen-1-yl)-1-pyrrolidiniumyl)-, 17-acetate, (2beta,3alpha,5alpha,16beta,17beta)- | ORG-9426 | ORG9426 | ORG 9426 | Esmeron | Esmerone | Zemuron | Rocuronium Bromide | Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, bromide
Chemical Information
Molecular Formula C32H53BrN2O4
CAS Registry Number 119302-91-9
SMILES CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Arrhythmia02.03.02.001---
Asthma10.01.03.010; 22.03.01.002---
Bronchospasm10.01.03.012; 22.03.01.004--
Electrocardiogram abnormal13.14.05.001---
Hiccups07.01.06.009; 22.12.01.001--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Injection site oedema08.02.03.024; 12.07.03.024---
Myopathy15.05.05.001---
Nausea07.01.07.001--
Paralysis17.01.04.004---
Pruritus23.03.12.001--
Pulmonary vascular resistance abnormality22.06.03.001; 24.03.08.002---
Rash23.03.13.001---
Rhonchi22.12.01.013---
Tachycardia02.03.02.007---
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Vascular resistance pulmonary increased13.14.03.020---
The 1th Page    1    Total 1 Pages